Osimertinib (Tagrisso)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses osimertinib (Tagrisso), 40 mg and 80 mg tablets, orally. Indication: As adjuvant therapy after tumour resection in patients with stage IB to stage IIIA non–small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.